Exome analysis of carotid body tumor

[1]  C. Tournigand,et al.  Polymerase proofreading domain mutations: New opportunities for immunotherapy in hypermutated colorectal cancer beyond MMR deficiency. , 2017, Critical reviews in oncology/hematology.

[2]  K. McDonald,et al.  Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma , 2017, Journal of Neuro-Oncology.

[3]  G. Krasnov,et al.  Molecular markers of paragangliomas/pheochromocytomas , 2017, Oncotarget.

[4]  Antonio L Amelio,et al.  Comprehensive Molecular Characterization of Pheochromocytoma and Paraganglioma. , 2017, Cancer cell.

[5]  Christopher A. Miller,et al.  Immunogenomics of Hypermutated Glioblastoma: A Patient with Germline POLE Deficiency Treated with Checkpoint Blockade Immunotherapy. , 2016, Cancer discovery.

[6]  Sung‐Min Ahn,et al.  The somatic POLE P286R mutation defines a unique subclass of colorectal cancer featuring hypermutation, representing a potential genomic biomarker for immunotherapy , 2016, Oncotarget.

[7]  Gennaro Ciliberto,et al.  Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy? , 2016, Cancer treatment reviews.

[8]  Masahiro Ito,et al.  Association between p53-binding protein 1 expression and genomic instability in oncocytic follicular adenoma of the thyroid. , 2016, Endocrine journal.

[9]  A. Vanderver,et al.  Magnetic resonance imaging spectrum of succinate dehydrogenase–related infantile leukoencephalopathy , 2016, Annals of neurology.

[10]  N. Goldstein,et al.  Mismatch repair deficiency associated with complete remission to combination programmed cell death ligand immune therapy in a patient with sporadic urothelial carcinoma: immunotheranostic considerations , 2015, Journal of Immunotherapy for Cancer.

[11]  Saskia D. Hiltemann,et al.  Discriminating somatic and germline mutations in tumor DNA samples without matching normals , 2015, Genome research.

[12]  H. Neumann,et al.  Profiling of Somatic Mutations in Phaeochromocytoma and Paraganglioma by Targeted Next Generation Sequencing Analysis , 2015, International journal of endocrinology.

[13]  Wen-Chang Chang,et al.  Down-regulation of ARNT promotes cancer metastasis by activating the fibronectin/integrin β1/FAK axis , 2015, Oncotarget.

[14]  B. Arun,et al.  Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian Cancers Associated with Brca1 and Brca2 Mutations Other than Breast and Ovarian , 2022 .

[15]  K. Cibulskis,et al.  Sporadic hemangioblastomas are characterized by cryptic VHL inactivation , 2014, Acta neuropathologica communications.

[16]  E. Mack,et al.  SDHB-Associated Paraganglioma in a Pediatric Patient and Literature Review on Hereditary Pheochromocytoma-Paraganglioma Syndromes , 2014, Case reports in endocrinology.

[17]  K. Hemminki,et al.  Novel genome-wide association study-based candidate loci for differentiated thyroid cancer risk. , 2014, The Journal of clinical endocrinology and metabolism.

[18]  Vladimir Vacic,et al.  Disease variants in genomes of 44 centenarians , 2014, Molecular genetics & genomic medicine.

[19]  Ramaswamy K. Iyer,et al.  Germline Variation in Cancer-Susceptibility Genes in a Healthy, Ancestrally Diverse Cohort: Implications for Individual Genome Sequencing , 2014, PloS one.

[20]  Jenny Welander,et al.  Rare germline mutations identified by targeted next-generation sequencing of susceptibility genes in pheochromocytoma and paraganglioma. , 2014, The Journal of clinical endocrinology and metabolism.

[21]  R. Serra,et al.  Surgical resection of carotid body paragangliomas: 10 years of experience. , 2014, American journal of surgery.

[22]  R. Ponce,et al.  Immunomodulation and lymphoma in humans , 2014, Journal of immunotoxicology.

[23]  M. Larsen,et al.  Hereditary Breast Cancer: Clinical, Pathological and Molecular Characteristics , 2014, Breast cancer : basic and clinical research.

[24]  S. Gallati,et al.  Mutations in SDHD lead to autosomal recessive encephalomyopathy and isolated mitochondrial complex II deficiency , 2013, Journal of Medical Genetics.

[25]  J. Valls,et al.  Usefulness of Negative and Weak–Diffuse Pattern of SDHB Immunostaining in Assessment of SDH Mutations in Paragangliomas and Pheochromocytomas , 2013, Endocrine Pathology.

[26]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[27]  A. Barlier,et al.  A MEN1 syndrome with a paraganglioma , 2013, European Journal of Human Genetics.

[28]  S. Srikantan,et al.  In vivo and in vitro oncogenic effects of HIF2A mutations in pheochromocytomas and paragangliomas. , 2013, Endocrine-related cancer.

[29]  Thomas Krausz,et al.  BAP1 and cancer , 2013, Nature Reviews Cancer.

[30]  Thomas Wiesner,et al.  Tumours associated with BAP1 mutations , 2013, Pathology.

[31]  E. Letouzé,et al.  Somatic NF1 inactivation is a frequent event in sporadic pheochromocytoma. , 2012, Human molecular genetics.

[32]  C. Larsson,et al.  Integrative genomics reveals frequent somatic NF1 mutations in sporadic pheochromocytomas. , 2012, Human molecular genetics.

[33]  W. Linehan,et al.  Succinate dehydrogenase kidney cancer: an aggressive example of the Warburg effect in cancer. , 2012, The Journal of urology.

[34]  K. Brown,et al.  A cryptic BAP1 splice mutation in a family with uveal and cutaneous melanoma, and paraganglioma , 2012, Pigment cell & melanoma research.

[35]  Cindy Follonier,et al.  Noncanonical mismatch repair as a source of genomic instability in human cells. , 2012, Molecular cell.

[36]  Larry N. Singh,et al.  Secondary variants in individuals undergoing exome sequencing: screening of 572 individuals identifies high-penetrance mutations in cancer-susceptibility genes. , 2012, American journal of human genetics.

[37]  I. Mader,et al.  Head and neck paragangliomas: clinical and molecular genetic classification , 2012, Clinics.

[38]  M. Urioste,et al.  MAX Mutations Cause Hereditary and Sporadic Pheochromocytoma and Paraganglioma , 2012, Clinical Cancer Research.

[39]  P. Dahia,et al.  An Update on the Genetics of Paraganglioma, Pheochromocytoma, and Associated Hereditary Syndromes , 2012, Hormone and Metabolic Research.

[40]  P. Söderkvist,et al.  Genetics and clinical characteristics of hereditary pheochromocytomas and paragangliomas. , 2011, Endocrine-related cancer.

[41]  S. Gruber,et al.  Spectrum and prevalence of FP/TMEM127 gene mutations in pheochromocytomas and paragangliomas. , 2010, JAMA.

[42]  Agnieszka Maliszewska,et al.  Research resource: Transcriptional profiling reveals different pseudohypoxic signatures in SDHB and VHL-related pheochromocytomas. , 2010, Molecular endocrinology.

[43]  G. Pfeifer,et al.  Environmental exposures and mutational patterns of cancer genomes , 2010, Genome Medicine.

[44]  R. Thakker.  Multiple endocrine neoplasia type 1 (MEN1). , 2010, Best practice & research. Clinical endocrinology & metabolism.

[45]  D. Adams,et al.  53BP1 loss rescues BRCA1 deficiency and is associated with triple-negative and BRCA-mutated breast cancers , 2010, Nature Structural &Molecular Biology.

[46]  W. Dinjens,et al.  Isocitrate dehydrogenase mutations are rare in pheochromocytomas and paragangliomas. , 2010, The Journal of clinical endocrinology and metabolism.

[47]  Fiona Douglas,et al.  Tumor risks and genotype–phenotype–proteotype analysis in 358 patients with germline mutations in SDHB and SDHD , 2010, Human mutation.

[48]  Steven P. Gygi,et al.  SDH5, a Gene Required for Flavination of Succinate Dehydrogenase, Is Mutated in Paraganglioma , 2009, Science.

[49]  T. Strom,et al.  SDHAF1, encoding a LYR complex-II specific assembly factor, is mutated in SDH-defective infantile leukoencephalopathy , 2009, Nature Genetics.

[50]  M. Stratton,et al.  The cancer genome , 2009, Nature.

[51]  G. Valk,et al.  Multiple Endocrine Neoplasia Type 1 (MEN 1) , 2009 .

[52]  A. Ligon,et al.  A germline mutation of the KIF1Bβ gene on 1p36 in a family with neural and nonneural tumors , 2008, Human Genetics.

[53]  M. Meyerson,et al.  The kinesin KIF1Bbeta acts downstream from EglN3 to induce apoptosis and is a potential 1p36 tumor suppressor. , 2008, Genes & development.

[54]  K. Pacak,et al.  Clinical presentations, biochemical phenotypes, and genotype-phenotype correlations in patients with succinate dehydrogenase subunit B-associated pheochromocytomas and paragangliomas. , 2007, The Journal of clinical endocrinology and metabolism.

[55]  M. Ichihara,et al.  RET and neuroendocrine tumors , 2006, Pituitary.

[56]  David P. Davis,et al.  Oncogenic BRAF is required for tumor growth and maintenance in melanoma models. , 2006, Cancer research.

[57]  Hee-Jin Kim,et al.  TP53BP2 locus is associated with gastric cancer susceptibility , 2005, International journal of cancer.

[58]  M. Cronin,et al.  Tumor Gene Expression and Prognosis in Breast Cancer Patients with 10 or More Positive Lymph Nodes , 2005, Clinical Cancer Research.

[59]  G. Heinze,et al.  Polymorphisms in exon 13 and intron 14 of the RET protooncogene: genetic modifiers of medullary thyroid carcinoma? , 2005, The Journal of clinical endocrinology and metabolism.

[60]  T. Furukawa,et al.  DSCP1, a novel TP53-inducible gene, is upregulated by strong genotoxic stresses and its overexpression inhibits tumor cell growth in vitro. , 2004, International journal of oncology.

[61]  M. Ichihara,et al.  RET and neuroendocrine tumors. , 2004, Cancer letters.

[62]  S. Iwata,et al.  Architecture of Succinate Dehydrogenase and Reactive Oxygen Species Generation , 2003, Science.

[63]  J. Strauchen.  Germ-line mutations in nonsyndromic pheochromocytoma. , 2002, The New England journal of medicine.

[64]  P. Rustin,et al.  Inborn errors of complex II--unusual human mitochondrial diseases. , 2002, Biochimica et biophysica acta.

[65]  I. Lossos,et al.  Apoptosis Stimulating Protein of p53 (ASPP2) Expression Differs in Diffuse Large B-cell and Follicular Center Lymphoma: Correlation with Clinical Outcome , 2002, Leukemia & lymphoma.

[66]  N. Hirokawa,et al.  Charcot-Marie-Tooth Disease Type 2A Caused by Mutation in a Microtubule Motor KIF1Bβ , 2001, Cell.

[67]  W. Simonds,et al.  Multiple endocrine neoplasia type 1: new clinical and basic findings , 2001, Trends in Endocrinology & Metabolism.

[68]  Michael I. Wilson,et al.  Targeting of HIF-α to the von Hippel-Lindau Ubiquitylation Complex by O2-Regulated Prolyl Hydroxylation , 2001, Science.

[69]  E. Friedman,et al.  Adrenal tumors in BRCA1/BRCA2 mutation carriers. , 2001, American journal of medical genetics.

[70]  B. Devlin,et al.  Mutations in SDHD, a mitochondrial complex II gene, in hereditary paraganglioma. , 2000, Science.

[71]  A. Dackiw,et al.  Screening for MEN1 mutations in patients with atypical endocrine neoplasia. , 1999, Surgery.

[72]  H. Kato,et al.  NF-κB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2 , 1999, Oncogene.

[73]  Bin Li,et al.  Stimulation of p53-mediated Transcriptional Activation by the p53-binding Proteins, 53BP1 and 53BP2* , 1998, The Journal of Biological Chemistry.

[74]  F. Collins,et al.  Germline mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. , 1997, Human molecular genetics.

[75]  A. Sparks,et al.  Identification of Novel Human WW Domain-containing Proteins by Cloning of Ligand Targets* , 1997, The Journal of Biological Chemistry.

[76]  N. Pavletich,et al.  Structure of the p53 Tumor Suppressor Bound to the Ankyrin and SH3 Domains of 53BP2 , 1996, Science.

[77]  N. Hirokawa,et al.  KIF1B, a novel microtubule plus end-directed monomeric motor protein for transport of mitochondria , 1994, Cell.

[78]  S. Fields,et al.  Two cellular proteins that bind to wild-type but not mutant p53. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[79]  W. C. Healey,et al.  Amplification monitoring and maintenance in schools. , 1989, ASHA.

[80]  C. Larsson,et al.  Multiple endocrine neoplasia type 1 gene maps to chromosome 11 and is lost in insulinoma , 1988, Nature.

[81]  S. Sheps,et al.  Carotid body tumor (chemodectoma). Clinicopathologic analysis of ninety cases. , 1971, American journal of surgery.

[82]  G. Finocchiaro,et al.  Hypermutations in gliomas: a potential immunotherapy target. , 2017, Discovery medicine.

[83]  E. Kebebew,et al.  Pediatric patients with pheochromocytoma and paraganglioma should have routine preoperative genetic testing for common susceptibility genes in addition to imaging to detect extra‐adrenal and metastatic tumors , 2017, Surgery.

[84]  A. Tincani,et al.  Carotid body tumor: retrospective analysis on 22 patients. , 2014, Sao Paulo medical journal = Revista paulista de medicina.

[85]  K. Köhrer,et al.  Complete sequencing and messenger ribonucleic acid expression analysis of the MEN I gene in adrenal cancer. , 2000, The Journal of clinical endocrinology and metabolism.

[86]  H. Kato,et al.  NF-kappaB subunit p65 binds to 53BP2 and inhibits cell death induced by 53BP2. , 1999, Oncogene.

[87]  T. Kawabe,et al.  Assignment of p53 binding protein (TP53BP2) to human chromosome band 1q42.1 by in situ hybridization. , 1997, Cytogenetics and cell genetics.

[88]  K. Kinzler,et al.  Cancer-susceptibility genes. Gatekeepers and caretakers. , 1997, Nature.

[89]  R. Thakker,et al.  Multiple endocrine neoplasia type 1 (MEN1). , 1994, European journal of cancer.